论文部分内容阅读
目的观察伊立替康联合顺铂二线治疗术后转移卵巢透明细胞癌(ovarian clear cell adenocarcinoma,OCCA)的临床效果及安全性。方法术后转移OCCA患者30例均给予伊立替康联合顺铂化疗,每21d为1个周期,治疗3个周期后评价临床效果及不良反应,并随访1a观察生存率。结果 30例中完成3个周期化疗者7例,完成4～5个周期化疗者4例,完成6个周期化疗者19例;早期转移(术后12个月以内转移者)、晚期转移(术后12个月以上转移者)患者总有效率、疾病控制率比较差异均无统计学意义(P>0.05);转移灶位于肝脏者总有效率优于转移灶位于盆腔、肺及淋巴结者(P<0.05);不良反应多为Ⅰ～Ⅱ级,患者可耐受。结论伊立替康联合顺铂方案适用于二线治疗术后肝脏转移OCCA患者,且不良反应轻。
Objective To observe the clinical efficacy and safety of irinotecan combined with cisplatin in the treatment of ovarian clear cell adenocarcinoma (OCCA). Methods Thirty patients with OCCA were treated with irinotecan plus cisplatin once every 21 days. After three cycles of treatment, the clinical effects and adverse reactions were evaluated. The survival rate was observed after follow-up of 1a. Results Among the 30 cases, 7 cases completed 3 cycles of chemotherapy, 4 cases completed 4 ~ 5 cycles of chemotherapy and 19 cases completed 6 cycles of chemotherapy. Early metastasis (metastasis within 12 months after operation), late metastasis There was no significant difference in total effective rate and disease control rate between the two groups (P> 0.05). The total effective rate of metastasis in the liver was better than that in the pelvic, lung and lymph node metastasis <0.05). Adverse reactions were grade Ⅰ ~ Ⅱ, patients were tolerant. Conclusion The irinotecan plus cisplatin regimen is suitable for patients with liver metastases of OCCA after second-line therapy with mild adverse reactions.